Michael Pappas, M.D.

Dr. Michael Pappas is a board-certified Family Medicine physician and researcher based in New York City, specializing in addiction, harm reduction, and psychedelic medicine. His work bridges clinical care, provider education, and health services research to address health disparities.

As Medical Director of Cardea, a psychedelic therapy program in NYC, Dr. Pappas leads clinical protocols for ketamine and other modalities while integrating harm reduction principles. He concurrently serves as Attending Physician for the Division of Addiction Services at Lincoln Hospital where he is leading clinical, research, and training initiatives to expand access to evidence-based addiction treatment and harm reduction services. For over three years, he served as Senior Clinician at OnPoint NYC, the nation’s first overdose prevention site, providing healthcare to marginalized people who use drugs or engage in sex work.

Dr. Pappas’ research interests include the intersection of psychedelics, substance use, harm reduction, and health disparities. He is currently a study physician for the NIH/NIDA-funded SOAR trial (Smartphones for Opiate Addiction Recovery), investigating AI-driven strategies to reduce overdose deaths. He is committed to advancing equitable models of healthcare through research, education, and clinical care.